Sequential treatment with irinotecan and doxifluridine: Optimal dosing schedule in murine models and in a phase I study for metastatic colorectal cancer

Chemotherapy

Volumn 51, Issue 1, 2005, Pages 32-39

  Mishima, Hideyuki ^a   Kato, Takeshi ^b   Yanagisawa, Mieko ^c   Tsujinaka, Toshimasa ^a   Nishisho, Isamu ^a   Tsujie, Masaki ^b   Fujimoto Ouchi, Kaori ^c   Tanaka, Yutaka ^c   Kikkawa, Nobuteru ^b  

^a OSAKA NATIONAL HOSPITAL   (Japan)

^b Minoh City Hospital   (Japan)

^c CHUGAI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Camptothecin; Colorectal cancer; Combination chemotherapy; Doxifluridine

Indexed keywords

DOXIFLURIDINE; IRINOTECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; FLOXURIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DOSE CALCULATION; DRUG EFFICACY; DRUG INDUCED DISEASE; FATIGUE; HYPERBILIRUBINEMIA; INTERMETHOD COMPARISON; MALE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; ADULT; AGED; ANIMAL; BAGG ALBINO MOUSE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COLORECTAL TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; HUMAN; LIVER TUMOR; LUNG TUMOR; LYMPH NODE METASTASIS; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NUDE MOUSE; PATHOLOGY; PHASE 1 CLINICAL TRIAL; XENOGRAFT;

ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DIARRHEA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLOXURIDINE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; MALE; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; TRANSPLANTATION, HETEROLOGOUS;

EID: 21344431617     PISSN: 00093157     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084416     Document Type: Article

References (19)

1. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2000;343:905-914.
2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alaki M, Gruia G, Awad L, Rougier P: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: A multicentre randomised trial. Lancet 2000;355:1041-1047.
3. Rothenberg ML, Meropol NJ, Poplin EA, Cutsem EV, Wadler S: Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel. J Clin Oncol 2001;19:3801-3807.
4. Grivicich I, Mans DRA, da Rocha AB, Dalla Costa HS, Schwartsmann G: The cytotoxicity of the irinotecan (CPT-11)-5-fluorouracil (5-FU) combination in human colon carcinoma cell lines is related to the sequence-dependent introduction of DNA lesions. Proc Am Assoc Cancer Res 1997;38:2133.
5. Vanhoefer U, Hapke G, Harstrick A, Achterrath W, Rustum YM, Seeber S: Schedule-dependent antitumor efficacy of irinotecan (CPT-11) and 5-fluorouracil (5-FU) in nude mice bearing colon tumor xenografts that are resistant to 5-FU. Ann Oncol 1998;9(suppl 4):634.
6. Cao S, Rustum YM: Synergistic antitumor activity of irinotecan in combination with 5-fluorouracil in rats bearing advanced colorectal cancer: Role of drug sequence and dose. Cancer Res 2000;60:3717-3721.
7. Cao S, Hapke G, Rustum YM: Enhanced antitumor activity of Xeloda by irinotecan in nude mice bearing human A253 and FaDu head and neck xenografts. Proc Am Assoc Cancer Res 2001;42:464.
8. Falcone A, Paolo AD, Masi G, Allegrini G, Danesi R, Lencioni M, Pfanner E, Comis S, Tacca MD, Conte P: Sequence effect of irinotecan and fluorouracil treatment on pharmacokinetics and toxicity in chemotherapy-naive metastatic colorectal cancer patients. J Clin Oncol 2001;19:3456-3462.
9. Yamao T, Shimada Y, Shirao K, Kondo H, Matsumura Y, Sugano K, Saito D, Ohtsu A, Boku N, Yoshida S, Sasaki Y, Ono K: Phase I study of CPT-11 combined with sequential 5-FU in metastatic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1996;15:1527.
10. Yoshioka T, Ohtsu A, Hyodo I, Shirao K, Saito S, Saito H, Nakamura A, Yamamichi N, Miyata Y, Hosokawa K, Iwase H, Yamamoto S: Phase II study of a combination of irinotecan and 5-day infusional S-fluorouracil in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol 2000;19:1142.
11. Ishitsuka H, Miwa M, Takemoto K, Fukuoka K, Itoga A, Maruyama HB: Role of uridine phosphorylase for antitumor activity of 5′-deoxy-5-fluorouridine. Gann 1980;71:112-123.
12. Niitani H, Kimura K, Saito T, Nakao I, Abe O, Urushizaki I, Ohta K, Yoshida Y, Kimura T, Kurihara M, Takeda C, Taguchi T, Terasawa T, Tominaga T, Furue H, Wakui A, Ogawa N: Phase II study of 5′-deoxy-5-fluorouridine (5′-DFUR) on patients with malignant cancer: Multi-institutional cooperative study (in Japanese). Jpn J Cancer Chemother 1985;12:2044-2051.
13. Ota K: Multicentre cooperative phase II study of 5′-deoxy-5- fluorouridine in the treatment of colorectal cancer. J Int Med Res 1988;16(suppl 2):19B-20B.
14. Ishitsuka H: Capecitabine: Preclinical pharmacology studies. Invest New Drugs 2000;18:343-354.
15. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N: Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11:909-913.
16. Niitani H, Kurihara M, Hasegawa K, Hatta Y, Suwa T, Tsuboi E, Yasui A, Yoshimori K, Kawachi M, Taguchi S, Sakimura K, Nishida Y, Furue H: Randomized comparison of continuous and intermittent oral administration of 5′-deoxy-5-fluorouridine in the treatment of advanced gastric cancer: A phase II trial by the Multi-Institutional Cooperative Study Group (in Japanese). Jpn J Cancer Chemother 1987;14:3345-3350.
17. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H: Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res 1998;58:685-690.
18. Koizumi W, Tanabe S, Nagaba S, Higuchi K, Nakayama N, Saigenji K, Nonaka M, Yago K: A double-blind, crossover, randomized comparison of granisetron and ramosetron for the prevention of acute and delayed cisplatin-induced emesis in patients with gastrointestinal cancer: Is patient preference a better primary endpoint? Chemotherapy 2003;49:316-323.
19. Tsavaris NB, Polyzos A, Gennatas K, Kosmas Ch, Vadiaka M, Dimitrakopoulos A, Macheras A, Papastratis G, Tsipras H, Margaris H, Papalambros E, Giannopoulos A, Koufos Ch: Irinotecan (CPT-11) in patients with advanced colon carcinoma relapsing after 5-fluorouracil-leucovorin combination. Chemotherapy 2002;48:94-99.